MARKET

CMMB

CMMB

Chemomab Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.03
-1.36
-6.36%
Opening 13:32 06/18 EDT
OPEN
20.67
PREV CLOSE
21.39
HIGH
21.00
LOW
19.72
VOLUME
171.19K
TURNOVER
--
52 WEEK HIGH
168.80
52 WEEK LOW
12.32
MARKET CAP
220.39M
P/E (TTM)
-0.2739
1D
5D
1M
3M
1Y
5Y
What You Need To Know About Chemomab Therapeutics Ltd.'s (NASDAQ:CMMB) Investor Composition
A look at the shareholders of Chemomab Therapeutics Ltd. ( NASDAQ:CMMB ) can tell us which group is most powerful...
Simply Wall St. · 1d ago
64 Biggest Movers From Friday
Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share.
Benzinga · 4d ago
Chemomab Therapeutics Is Heating Up And Could See A Move Soon
Chemomab Therapeutics LTD. (NASDAQ: CMMB) shares are trading higher Friday as retail traders continue to push stocks higher.
Benzinga · 06/11 16:27
Novan, Vaxart leads healthcare gainers; Orphazyme, Curis among major losers
Gainers: Novan (NOVN) +81%, Aptinyx (APTX) +25%, Vaxart (VXRT) +39%, Progenity (PROG) +28%, Chemomab Therapeutics (CMMB) +9%.Losers: Orphazyme (ORPH) -41%, Curis (CRIS) -32%, Aptose Biosciences (APTO) -30%, Galecto (GLTO) -22%, Heat Biologics (HTBX) -23%.
Seekingalpha · 06/11 15:00
Thinking about buying stock in Novan, Chemomab Therapeutics, Precigen, ChemoCentryx, or Senseonics?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOVN, CMMB, PGEN, CCXI, and SENS.
PR Newswire - PRF · 06/11 12:30
Healthcare names dominate premarket gainers
Amesite (AMST) +61%.GBS (GBS) +40%.Novan (NOVN) +37% on positive results for SB206 in skin infection.Precigen (PGEN) +31% on positive topline results from phase 1b/2a study of AG019 ActoBiotics™.Protagenic Therapeutics (PTIX) +28%.Magnachip Semiconductor
Seekingalpha · 06/11 12:28
Chemomab Announces Poster Presentation at the International Liver Congress 2021 (EASL)
/PRNewswire/ -- . (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced a poster presentation at the International Liver Cong...
PR Newswire - PRF · 06/10 11:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers
Benzinga · 06/09 20:44
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CMMB. Analyze the recent business situations of Chemomab Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CMMB stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 15
Institutional Holdings: 3.18M
% Owned: 28.93%
Shares Outstanding: 11.00M
TypeInstitutionsShares
Increased
1
1.68K
New
8
2.87M
Decreased
1
176
Sold Out
3
6.68K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.94%
Pharmaceuticals & Medical Research
-1.15%
Key Executives
Chairman/Director
Stephen Squinto
Chief Executive Officer/Chief Scientific Officer/Director
Adi Mor
Chief Financial Officer
Sigal Fattal
Senior Vice President
Ronald Knickerbocker
Vice President
Sean Daly
Vice President - Research & Development
Michal Gilon Ohev-Zion
Other
Aaron Aharon
Other
Joseph Ginossar
Other
David Kerstein
Director
Neil Cohen
Director
Nissim Darvish
Director
Joel Maryles
Director
Alan Moses
Director
Claude Nicaise
Independent Director
Lawrence Howard
No Data
  • All
  • Financials
  • Insiders
More
About CMMB
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Webull offers kinds of Chemomab Therapeutics Ltd - ADR stock information, including NASDAQ:CMMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMMB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CMMB stock methods without spending real money on the virtual paper trading platform.